TP53 and lung adenocarcinoma: Taken together, these findings emphasize the diverse immunosuppressive effects of TP53 mutations and their role in promoting immune escape of lung adenocarcinoma cells, potentially contributing to resistance mechanisms against checkpoint inhibitor therapy.